Uterine cancer deaths continue to rise despite advances in other cancers. Many patients who cannot undergo surgery rely on progestin therapy, which often fails. This research tests dozens of progestins on patient tumor and immune cells, identifying five more effective candidates. The goal is safer, personalised, fertility-preserving treatment for women with uterine cancer.

This research investigates a novel two-drug therapy for ovarian cancer that kills cancer cells without harming healthy tissues and partially reactivates the suppressed immune system. The PhD work explores how this immune “reawakening” occurs, aiming to identify new strategies to enhance it and create more effective, resistance-proof treatments.